03.04.2017
MorphoSys AG DE0006632003
DGAP-News: MorphoSys Nominates New Candidate for Supervisory Board
DGAP-News: MorphoSys AG / Key word(s): Change of Personnel/Miscellaneous
MorphoSys Nominates New Candidate for Supervisory Board (news with
additional features)
03.04.2017 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg/Munich, Germany, April 3, 2017
MorphoSys Nominates New Candidate for Supervisory Board
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY)
announced today that it has published its agenda for the Company's ordinary
Annual General Meeting (AGM), which will take place on Wednesday, May 17,
2017.
MorphoSys's Supervisory Board has nominated Krisja Vermeylen as candidate to
be elected as a new Supervisory Board member at the Company's AGM. Ms.
Vermeylen will replace Karin Eastham, who has resigned from her Supervisory
Board mandate for personal reasons with effect from the conclusion of the
AGM 2017. Furthermore the Supervisory Board has proposed to re-elect Dr.
Frank Morich, Wendy Johnson and Klaus Kühn, whose terms of office would have
expired with the conclusion of the AGM 2017.
"We are delighted that with Ms. Vermeylen we can present a highly qualified
candidate with extensive industry expertise for MorphoSys's Supervisory
Board. Ms. Vermeylen brings to our Board significant experience in product
management, marketing and commercialization of pharmaceuticals," commented
Dr. Gerald Möller, Chairman of the Supervisory Board of MorphoSys AG. "On
behalf of the Company, I would like to thank Ms. Eastham for her invaluable
support and contribution to MorphoSys over the last five years."
Ms. Vermeylen currently serves as Senior Vice President Corporate People &
Organisation at Novo Nordisk A/S, Bagsvaerd, Denmark. Over the last 20
years, she has worked with Novo Nordisk in various management positions,
including as General Manager for Belgium and Luxemburg (BeLux), France and,
most recently, Germany. Before joining Novo Nordisk, Ms. Vermeylen worked
for several years at Pharmacia (today Pfizer). Ms. Vermeylen is a pharmacist
by training and holds a master's degree in pharmaceutical sciences from the
University of Antwerp (UIA, RUCA), Belgium.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology
in the pharmaceutical industry. By successfully applying this and other
patented technologies, MorphoSys has become a leader in the field of
therapeutic antibodies, one of the fastest-growing drug classes in human
healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment
of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a
few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys, visit
http://www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R),
Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R)
and LanthioPep(R) are registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies. The forward-looking statements contained
herein represent the judgment of MorphoSys as of the date of this release
and involve risks and uncertainties. Should actual conditions differ from
the Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these
forward-looking statements as far as the wording of the relevant press
release is concerned.
For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
[email protected]
---------------------------------------------------------------------------
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=BNYTQPELTG
Document title: Media Release
---------------------------------------------------------------------------
03.04.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: [email protected]
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
561019 03.04.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
MorphoSys AG ISIN: DE0006632003 können Sie bei EQS abrufen
Biotechnologie , 663200 , MOR , XETR:MOR